ReviewBlood2012
How I treat pediatric acute myeloid leukemia.
Review in Blood, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prognostic significance of cytogenetic and molecular features in pediatric acute myeloid leukemia: a meta-analysis.BMC cancer · 2025Pooled it
- Association between CEBPE Variant and Childhood Acute Leukemia Risk: Evidence from a Meta-Analysis of 22 Studies.PloS one · 2015Pooled it
- Homoharringtonine-Based Induction Regimen Improved the Remission Rate and Survival Rate in Chinese Childhood AML: A Report From the CCLG-AML 2015 Protocol Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Treatment outcomes and prognostic factors in children diagnosed with acute myeloid leukaemia in Uganda.BMC cancer · 2025Article
- Development and validation of a promising 5-gene prognostic model for pediatric acute myeloid leukemia.Molecular biomedicine · 2024Article
- Acute kidney injury and childhood acute myeloid leukemia.Pediatric nephrology (Berlin, Germany) · 2022Article
- Integrated Genomic Analysis Identifies UBTF Tandem Duplications as a Recurrent Lesion in Pediatric Acute Myeloid Leukemia.Blood cancer discovery · 2022Article
- Intensive monitoring of minimal residual disease and chimerism after allogeneic hematopoietic stem cell transplantation for acute leukemia in children.Bone marrow transplantation · 2021Article
- Prognostic significance of measurable residual disease based on multiparameter flow cytometry in childhood acute myeloid leukemia.Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2021Article
- Targeted Therapy in Pediatric AML: An Evolving Landscape.Paediatric drugs · 2021Review
- Comparison of total body irradiationHaematologica · 2021Article
- The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML.Blood cancer journal · 2021Article
- [Clinical features and prognosis of pediatric acute megakaryocytic leukemia].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2021Article
- Cytogenetic characteristics of and prognosis for acute myeloid leukemia in 107 children.Asian biomedicine : research, reviews and news · 2021Article
- A three-gene signature and clinical outcome in pediatric acute myeloid leukemia.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Article
- A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation.Blood · 2021Article
- Role of Metastasis Suppressor KAI1/CD82 in Different Cancers.Journal of oncology · 2021Review
- Treatments for children and adolescents with AML.Blood research · 2020Review
- Nucleophosmin mutations confer an independent favorable prognostic impact in 869 pediatric patients with acute myeloid leukemia.Blood cancer journal · 2020Article
- Is Acute Myeloblastic Leukemia in Children Under 2 Years of Age a Specific Entity? A Report from the FRENCH ELAM02 Study Group.HemaSphere · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Acute myeloid leukemia is a heterogeneous disease that accounts for approximately 20% of acute leukemias in children and adolescents. Despite the lack of targeted therapy for most subtypes and a dearth of new agents, survival rates have reached approximately 60% for children treated on clinical trials in developed countries. Most of the advances have been accomplished by better risk classification, the implementation of excellent supportive care measures, adaptation of therapy on the basis of each patient's response to therapy, and improvements in allogeneic hematopoietic stem cell transplantation. However, it is unlikely that further gains can be made through these measures alone. In this regard, high-resolution, genome-wide analyses have led to greater understanding of the pathogenesis of this disease and the identification of molecular abnormalities that are potential targets of new therapies. The development of molecularly targeted agents, some of which are already in clinical trials, holds great promise for the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.